CZ302157B6 - Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra - Google Patents
Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra Download PDFInfo
- Publication number
- CZ302157B6 CZ302157B6 CZ20004489A CZ20004489A CZ302157B6 CZ 302157 B6 CZ302157 B6 CZ 302157B6 CZ 20004489 A CZ20004489 A CZ 20004489A CZ 20004489 A CZ20004489 A CZ 20004489A CZ 302157 B6 CZ302157 B6 CZ 302157B6
- Authority
- CZ
- Czechia
- Prior art keywords
- weight
- cyclophosphamide
- talc
- magnesium stearate
- parts
- Prior art date
Links
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960004397 cyclophosphamide Drugs 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000454 talc Substances 0.000 claims abstract description 20
- 229910052623 talc Inorganic materials 0.000 claims abstract description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 18
- 229920002261 Corn starch Polymers 0.000 claims abstract description 16
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 16
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 15
- 239000008120 corn starch Substances 0.000 claims abstract description 15
- 229960001021 lactose monohydrate Drugs 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 5
- 235000011187 glycerol Nutrition 0.000 claims abstract description 5
- 235000010355 mannitol Nutrition 0.000 claims abstract description 5
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 4
- 235000010980 cellulose Nutrition 0.000 claims abstract description 4
- 239000001913 cellulose Substances 0.000 claims abstract description 4
- 229920002678 cellulose Polymers 0.000 claims abstract description 4
- 229920001577 copolymer Polymers 0.000 claims abstract description 4
- 239000006185 dispersion Substances 0.000 claims abstract description 4
- 239000000314 lubricant Substances 0.000 claims abstract description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 4
- 239000008117 stearic acid Substances 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 3
- 239000002706 dry binder Substances 0.000 claims abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 claims description 3
- 229950002273 simeticone Drugs 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 235000019759 Maize starch Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- RTAQQCXQSZGOHL-OIOBTWANSA-N titanium-45 Chemical compound [45Ti] RTAQQCXQSZGOHL-OIOBTWANSA-N 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 abstract description 8
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 abstract description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 abstract description 2
- 238000005507 spraying Methods 0.000 abstract description 2
- 238000000265 homogenisation Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 229940083037 simethicone Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VDUIFGQTMVINBA-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)tetracosan-3-one Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)C(O)(CO)CO VDUIFGQTMVINBA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19826517A DE19826517B4 (de) | 1998-06-15 | 1998-06-15 | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ20004489A3 CZ20004489A3 (cs) | 2001-08-15 |
| CZ302157B6 true CZ302157B6 (cs) | 2010-11-18 |
Family
ID=7870877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20004489A CZ302157B6 (cs) | 1998-06-15 | 1999-06-08 | Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20010046504A1 (enExample) |
| EP (1) | EP1089739B1 (enExample) |
| JP (1) | JP4891478B2 (enExample) |
| KR (1) | KR100679872B1 (enExample) |
| CN (1) | CN1177590C (enExample) |
| AR (1) | AR019670A1 (enExample) |
| AT (1) | ATE310523T1 (enExample) |
| AU (1) | AU771284B2 (enExample) |
| BG (1) | BG65253B1 (enExample) |
| BR (1) | BR9911276A (enExample) |
| CA (1) | CA2333682C (enExample) |
| CO (1) | CO5070588A1 (enExample) |
| CZ (1) | CZ302157B6 (enExample) |
| DE (3) | DE19826517B4 (enExample) |
| DK (1) | DK1089739T3 (enExample) |
| ES (1) | ES2255276T3 (enExample) |
| HU (1) | HU226528B1 (enExample) |
| IL (2) | IL139944A0 (enExample) |
| NO (1) | NO325154B1 (enExample) |
| NZ (1) | NZ508888A (enExample) |
| PL (1) | PL193398B1 (enExample) |
| RU (1) | RU2236231C2 (enExample) |
| SK (1) | SK286185B6 (enExample) |
| TR (1) | TR200003702T2 (enExample) |
| TW (1) | TWI242450B (enExample) |
| UA (1) | UA75566C2 (enExample) |
| WO (1) | WO1999065499A1 (enExample) |
| ZA (1) | ZA200006998B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT500063A1 (de) | 1999-11-23 | 2005-10-15 | Sandoz Ag | Beschichtete tablettenkerne |
| ES2377729T3 (es) | 2002-02-21 | 2012-03-30 | Valeant International (Barbados) Srl | Formulaciones de liberación modificada de al menos una forma de tramadol |
| DE102005008797A1 (de) * | 2005-02-25 | 2006-09-07 | Baxter International Inc., Deerfield | Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| EP2745833A1 (en) * | 2012-12-21 | 2014-06-25 | Institut Gustave Roussy | Soluble, dispersible or orodispersible tablets comprising cyclophosphamide |
| US10016447B2 (en) | 2014-09-26 | 2018-07-10 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition having improved content uniformity |
| HRP20201405T1 (hr) | 2016-03-17 | 2020-11-27 | F. Hoffmann - La Roche Ag | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0519099A1 (en) * | 1988-09-09 | 1992-12-23 | Bristol-Myers Squibb Company | Direct compression cyclophosphamide tablet |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110814A (en) * | 1989-01-11 | 1992-05-05 | Asta Pharma Ag | Azelastine and its salts used to combat psoriasis |
| UA26305A (uk) * | 1990-07-16 | 1999-08-30 | Аста Медіка Аг | Таблетка, спосіб її одержаhhя, граhулят та спосіб одержаhhя граhулята |
| DE59101431D1 (de) * | 1990-07-16 | 1994-05-26 | Asta Medica Ag | Tablette und Granulat welche als Wirkstoff Mesna enthalten. |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| GB9115160D0 (en) * | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
| GB9119983D0 (en) * | 1991-09-19 | 1991-11-06 | Erba Carlo Spa | Dihydropyridine derivatives useful in antitumor therapy |
| DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| JP3049095B2 (ja) * | 1996-02-22 | 2000-06-05 | サムジン ファーマシューチカル カンパニー，リミテッド | 新規抗ウイルス性置換ピリミジンジオン単素炭素環式ヌクレオシド誘導体及びその製造方法とこれを活性成分として含有する組成物 |
| JPH11322596A (ja) * | 1998-05-12 | 1999-11-24 | Shionogi & Co Ltd | 白金錯体および環状リン酸エステルアミドを含有する抗癌剤 |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
-
1998
- 1998-06-15 DE DE19826517A patent/DE19826517B4/de not_active Expired - Fee Related
-
1999
- 1999-06-08 JP JP2000554378A patent/JP4891478B2/ja not_active Expired - Fee Related
- 1999-06-08 ES ES99927902T patent/ES2255276T3/es not_active Expired - Lifetime
- 1999-06-08 CA CA002333682A patent/CA2333682C/en not_active Expired - Fee Related
- 1999-06-08 DK DK99927902T patent/DK1089739T3/da active
- 1999-06-08 DE DE59912829T patent/DE59912829D1/de not_active Expired - Lifetime
- 1999-06-08 PL PL99344832A patent/PL193398B1/pl not_active IP Right Cessation
- 1999-06-08 AT AT99927902T patent/ATE310523T1/de active
- 1999-06-08 TR TR2000/03702T patent/TR200003702T2/xx unknown
- 1999-06-08 HU HU0102788A patent/HU226528B1/hu not_active IP Right Cessation
- 1999-06-08 KR KR1020007014142A patent/KR100679872B1/ko not_active Expired - Fee Related
- 1999-06-08 EP EP99927902A patent/EP1089739B1/de not_active Expired - Lifetime
- 1999-06-08 RU RU2001101903/15A patent/RU2236231C2/ru not_active IP Right Cessation
- 1999-06-08 CZ CZ20004489A patent/CZ302157B6/cs not_active IP Right Cessation
- 1999-06-08 CN CNB998074330A patent/CN1177590C/zh not_active Expired - Fee Related
- 1999-06-08 NZ NZ508888A patent/NZ508888A/en not_active IP Right Cessation
- 1999-06-08 WO PCT/EP1999/003920 patent/WO1999065499A1/de not_active Ceased
- 1999-06-08 BR BR9911276-0A patent/BR9911276A/pt not_active Application Discontinuation
- 1999-06-08 IL IL13994499A patent/IL139944A0/xx active IP Right Grant
- 1999-06-08 AU AU45085/99A patent/AU771284B2/en not_active Ceased
- 1999-06-08 SK SK1858-2000A patent/SK286185B6/sk not_active IP Right Cessation
- 1999-06-09 TW TW088109644A patent/TWI242450B/zh not_active IP Right Cessation
- 1999-06-10 DE DE29921466U patent/DE29921466U1/de not_active Expired - Lifetime
- 1999-06-11 CO CO99036819A patent/CO5070588A1/es unknown
- 1999-06-15 AR ARP990102862A patent/AR019670A1/es not_active Application Discontinuation
- 1999-06-15 US US09/333,256 patent/US20010046504A1/en not_active Abandoned
- 1999-08-06 UA UA2001010222A patent/UA75566C2/uk unknown
-
2000
- 2000-11-27 IL IL139944A patent/IL139944A/en not_active IP Right Cessation
- 2000-11-28 ZA ZA200006998A patent/ZA200006998B/en unknown
- 2000-12-12 NO NO20006325A patent/NO325154B1/no not_active IP Right Cessation
-
2001
- 2001-01-10 BG BG105139A patent/BG65253B1/bg unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0519099A1 (en) * | 1988-09-09 | 1992-12-23 | Bristol-Myers Squibb Company | Direct compression cyclophosphamide tablet |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6914141B2 (en) | Clopidogrel bisulfate tablet formulation | |
| KR100348842B1 (ko) | 염기성물질로안정화된약제학적조성물 | |
| US5419917A (en) | Controlled release hydrogel formulation | |
| US5047246A (en) | Direct compression cyclophosphamide tablet | |
| CZ292069B6 (cs) | Farmaceutický přípravek zahrnující moxifloxacin, způsob výroby a použití tohoto přípravku | |
| US20100008988A1 (en) | Tablet compositions of amine polymers | |
| KR20010086062A (ko) | 고가용성 약물용 서방성 메트리스 시스템 | |
| EP1266657A1 (en) | Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride | |
| EP0315964A1 (en) | A novel pharmaceutical composition comprising exifone and water-soluble polymer | |
| CA1298196C (en) | Clodronate-containing medicaments and a process for the preparation thereof | |
| CZ302157B6 (cs) | Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra | |
| SK281193B6 (sk) | Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy | |
| CS261791A3 (en) | Process for preparing preparations in the form of tablets or coated tablets containing light, heat and moisture sensitive active component having a monoclinic crystal structure | |
| SK283249B6 (sk) | Tableta vyrobiteľná priamym tabletovaním, obsahujúca aktívnu látku kyselinu 4-amino-1-hydroxybutylidén-1,1-bisfosfónovú a spôsob jej výroby | |
| CA2355239C (en) | Pharmaceutical formulations | |
| WO2007134845A2 (en) | Olanzapine pharmaceutical composition | |
| SK15542003A3 (sk) | Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme | |
| WO2015044394A1 (en) | Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof | |
| SK285236B6 (sk) | Farmaceutická kompozícia obsahujúca ciprofloxacína spôsob jej prípravy | |
| PL196485B1 (pl) | Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania | |
| US20030229101A1 (en) | Tablets comprising ciprofloxacin hydrochloride | |
| WO2010099150A1 (en) | Pharmaceutical tablet and process | |
| JP2019189554A (ja) | 溶出性を改善させた医薬組成物 | |
| WO1996012476A1 (en) | Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist | |
| MXPA00012079A (en) | Cyclophosphamide coated tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20140608 |